Stocks Health care INBX
NASDAQ · Health careInhibrx Biosciences, Inc. (INBX)
It posted a net loss of $138.2M. In fiscal 2025 capital spending exceeded operating cash flow by $129.8M. At June 30, 2026 it held $133.3M in cash against $176.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Inhibrx Biosciences, Inc. does
Inhibrx Biosciences, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INBX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.3M | -$140.1M | -$9.04 | -$129.8M |
| 2024 | $200K | $1.7B | $112.62 | -$197M |
| 2024 | $1.8M | -$241.4M | -$20.48 | -$197.9M |
Latest SEC filings
What Inhibrx Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 3, 2026Passive stake (5% or more) SCHEDULE 13G
- July 16, 2026
- June 15, 2026
- June 3, 2026
Questions about INBX
What does Inhibrx Biosciences, Inc. do?
Inhibrx Biosciences, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INBX.
Is Inhibrx Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $138.2M.
When did Inhibrx Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 23, 2026.
Similar companies
Follow INBX
Get an email when Inhibrx Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow INBX: get an email when it filesWhere the numbers come from
Financial figures are the values Inhibrx Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.